Progress of research on drug therapies for SARS-CoV-2 variants infections
10.11816/cn.ni.2025-246458
- VernacularTitle:新型冠状病毒突变株感染药物治疗研究进展
- Author:
Jiayi ZHANG
1
;
Xiaodong HUANG
;
Weidong LI
;
Xiaowen HAN
;
Zhenyu YIN
;
Lei GAO
;
Ewetse Paul MASWIKITI
;
Bin MA
;
Ying ZHANG
;
Hao CHEN
Author Information
1. 兰州大学第二临床医学院,甘肃兰州 730030;兰州大学第二医院肿瘤外科,甘肃兰州 730030
- Publication Type:Journal Article
- Keywords:
COVID-19;
SARS-CoV-2;
Variant;
Drug;
Immunotherapy
- From:
Chinese Journal of Nosocomiology
2025;35(10):1577-1583
- CountryChina
- Language:Chinese
-
Abstract:
Thousands of variant gene sequences of SARS-CoV-2 have been emerged since the COVID-19 epidemic broke out in Dec.2019.Alpha(B.1.1.7),Beta(B.1.351),Gamma(P.1),Delta(B.1.617.2)and Omicron(B.1.1.529)were the most representative variants.With the continuous emergence of new variants,the predomi-nant strain in the global pandemic as of Jan.2025 is the Omicron BA.2.86-derived mutant,JN.1.The effectiveness of drugs against Omicron variants remains a key research focus in the treatment of SARS-CoV-2 infections.The infectiousness and pathogenicity of the variants altered remarkably due to mutations in the genome on S protein of the mutant strains,and these emerging variants are more likely to evade immunity and were more infectious than the previous prevalent variants.During the process of combating with the constantly emerging novel variants,drugs showed various effects on treatment of diseases caused by different variants.New drugs and treatment coun-termeasures are constantly updated with the prevalence of various variants.The current status of research on pres-ent drugs for treatment of SARS-CoV-2 and the therapeutic effects on emerging variants are reviewed in the article so as to provide reference for prevention and treatment of the upcoming evolved variants.
